A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Chinese COVID-19 Vaccine Exhibits Disappointing Results


Preliminary data on the CoronaVac—a COVID-19 vaccination manufactured by the Beijing-based biopharmaceutical company Sinovac—demonstrated only about 50% efficacy in preventing mild and severe COVID-19 illness in a Brazilian clinical trial. CoronaVac had shown better results in trials conducted in Turkey and Indonesia, but its effectiveness was never close to the 90% to 95% efficacy offered by the Pfizer and Moderna vaccines. Public health officials suggest there remains a role for CoronaVac, especially among nations with out-of-control spread, like Brazil. In the Brazilian clinical trial, 167 individuals who received a placebo and 85 who were inoculated developed COVID-19 illness out of 9,200 test subjects; however, none of those infected with the novel coronavirus required hospitalization. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy